DB3, LLC (FKA THE DASCHLE GROUP)

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC · Pharmaceutical manufacturer

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Health Issues

Research, development, and reimbursement of psychedelics for mental health conditions

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.